Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MMP3 | P08254 | 1/20 | 0.58 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | AKT2 | P31751 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10546871 | 0.96 | MEN1 (0.91) | KMT2AMEN1L3MBTL1KDM4ELMNA | |
| SCHEMBL9104678 | 0.96 | MEN1 (0.91) | KMT2AMEN1L3MBTL1KDM4ELMNA | |
| SCHEMBL13950894 | 0.89 | KDM4E (0.78) | KMT2AMEN1L3MBTL1KDM4ELMNA | |
| SCHEMBL28037189 | 0.88 | KMT2A (0.79) | KMT2AMEN1L3MBTL1KDM4ELMNA | |
| SCHEMBL28037634 | 0.88 | KMT2A (0.79) | KMT2AMEN1L3MBTL1KDM4ELMNA | |
| SCHEMBL9891119 | 0.87 | KMT2A (0.76) | KMT2AMEN1L3MBTL1KDM4ELMNA | |
| SCHEMBL24590007 | 0.86 | KDM4E (0.75) | KMT2AMEN1L3MBTL1KDM4ELMNA | |
| SCHEMBL13726198 | 0.86 | KDM4E (0.75) | KMT2AMEN1L3MBTL1KDM4ELMNA | |
| SCHEMBL22769176 | 0.86 | KDM4E (0.75) | KMT2AMEN1L3MBTL1KDM4ELMNA | |
| SCHEMBL22769174 | 0.86 | KDM4E (0.75) | KMT2AMEN1L3MBTL1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763938-B2 | Substituted quinoxalines as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-09-19 | — | — | US | claimed |
| US-20160317533-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | MERCK PATENT GMBH (DE) | 2016-11-03 | — | — | US | claimed |
| US-20150374687-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | MERCK PATENT GMBH (DE) | 2015-12-31 | — | — | US | claimed |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | GEORGETOWN UNIVERSITY (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | GEORGETOWN UNIVERSITY (US) | 2023-07-06 | — | — | US | disclosed |
| US-9889131-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889131-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2393787-B1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9763938-B2 | Substituted quinoxalines as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-09-19 | — | — | US | disclosed |
| EP-2953939-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | Merck Patent GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | UNITED STATES GOVERNMENT | 2015-03-05 | — | — | US | disclosed |
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | UNITED STATES GOVERNMENT | 2015-03-05 | — | — | US | disclosed |
| WO-2014121885-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | disclosed |
| US-8802687-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802687-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010091384-A2 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | CDH1, ICAM1, S100A11 | KMT2A 2318/4885MEN1 1025/4885L3MBTL1 2988/4885 |
| US-20150374687-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | GRM4, GRIK4, GRIA4 | KMT2A 793/4885MEN1 4409/4885L3MBTL1 3271/4885 |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | CDH1, DSC1, EPCAM | KMT2A 2020/4885MEN1 91/4885L3MBTL1 2265/4885 |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | CDH1, GPR119, FABP4 | KMT2A 2427/4885MEN1 1468/4885L3MBTL1 3322/4885 |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | CDH1, ICAM1, S100A11 | KMT2A 2318/4885MEN1 1025/4885L3MBTL1 2988/4885 |
| US-20160317533-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | GRM4, GRIA4, GRIK4 | KMT2A 1113/4885MEN1 4389/4885L3MBTL1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.